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Systemic sclerosis (SSc) is an autoimmune rheumatic disease with heterogeneous clinical manifestations and a 
variable course in which the severity of the pathology dictates the disease prognosis and course. Among autoimmune 
rheumatic diseases, SSc has the highest mortality rate among all rheumatic diseases, though there are exciting 
new therapeutic targets that appear to halt the progression of SSc manifestations such as skin or lung fibrosis. In 
selected patients, high- intensity regimens with autologous stem cell transplantation can favorably modify the course. 
In what was once thought to be an untreatable disease, targeted therapies have now changed the outlook of SSc to 
a treatable disorder. Herein, we discuss the targeted therapies modifying the outlook on selected organ involvement 
and creating opportunities for future treatment. We also present a framework for defining low disease activity in SSc.
INTRODUCTION
Systemic sclerosis (SSc) is a rare disease characterized by 
vasculopathy and fibrosis in the skin and internal organs (1). The 
proposed pathophysiology is a triad of vascular damage with 
endothelial dysfunction, dysregulation of innate and  adaptive 
immunity, and widespread fibrosis in multiple organs (2,3). 
The mortality rate in SSc is higher than in any other rheumatic 
disease (4,5).
In contrast to rheumatoid arthritis (RA), the concept and use 
of disease- modifying therapies that attenuate or reverse pathol-
ogy and clinical impact are not currently applied to SSc. The 
notion of disease modification in SSc has now advanced to reality 
based on data from recent clinical trials. Autologous hematopo-
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i etic stem cell transplantation (HSCT) trials in diffuse cutaneous 
SSc (dcSSc) have demonstrated survival benefit, including mean-
ingful improvements in skin, lung fibrosis, and health- related 
quality of life (HRQoL) (6–9).
In this report, we discuss specific treatments that have mod-
ified the course of organ- specific manifestations in SSc and have 
started the conversation on defining low disease activity in SSc.
What is disease- modifying therapy?
We borrow the concept of “disease- modifying therapy” from 
the use of disease- modifying antirheumatic drugs (DMARDs) 
and biologic response modifiers in RA. In the past 3 decades, 
RA treatment has evolved from symptom management to the 
implementation of DMARDs and/or biologic response modifiers. 
The early institution of DMARDs or biologic response modifiers in 
RA induces clinical remission, reduces the frequency of relapse, 
abrogates joint damage, preserves physical function, improves 
HRQoL, and prevents long- term disability (10). Similarly, we can 
conceptualize disease- modifying therapy in SSc as therapies 
or medication regimens that positively impact the disease course 
by stabilizing and potentially improving organ function. This, in 
turn, improves HRQoL and reduces morbidity and mortality (11).
Natural history of the disease
Understanding the natural history of the SSc disease process 
is vital to the concept of disease- modifying therapy in the context 
of timing and patient selection. Early clinical features include Ray-
naud’s phenomenon (RP) and gastroesophageal reflux disease (12). 
Skin fibrosis is a pathologic hallmark of the disease and is frequently 
preceded by puffy and swollen fingers. Patients with puffy fingers, 
definite RP, typical nailfold capillary changes, and the presence 
of SSc- specific antibodies can be considered to have very- early- 
diagnosed SSc (13,14). Thereafter, patients may progress to 1 of 
3 clinical disease subsets based on the extent of skin involvement.
Patients with skin involvement restricted to the limbs distal to 
the elbows or knees, with or without face involvement, are classified 
as having limited cutaneous SSc (lcSSc). Patients with distal as well 
as proximal involvement (including the torso) are classified as having 
dcSSc. A small subset of patients without skin involvement but who 
have scleroderma- specific antibodies and internal organ involve-
ment are considered to have SSc without scleroderma (15–17). This 
differentiation is important as dcSSc is associated with higher mor-
bidity and mortality, mainly due to more severe and/or progressive 
internal organ involvement (18). However, this differentiation of the 
clinical phenotypes is an oversimplification of the disease process.
The biology of SSc is complex, heterogeneous, and dyna-
mic, with sequentially overlapping features of inflammation, 
autoimmu ni ty, tissue injury, and fibrosis. Skin thickness is generally 
 progressive within the first 3 years after the start of RP in dcSSc, 
but there is individual variability (15,16). The extent and severity 
of skin involvement in dcSSc generally level off by years 4 and 5, 
and then clinically appear to improve both via de- remodeling and 
atrophy (19). Only a minority of patients have a new emergence of 
progressive cutaneous involvement beyond 5 years after disease 
onset. There is an increased risk for the development of internal 
organ involvement during the progressive skin phase. For exam-
ple, in dcSSc, most internal organ involvement (lung, renal, car-
diac, and gastrointestinal) occurs in the first 3–5 years after disease 
onset (Figure 1) (16). In the early phase of dcSSc, internal organ 
involvement—although clinically silent—may evolve at the same 
time as progressive skin disease. There are, however, exceptions. 
For example, pulmonary arterial hypertension (PAH) is generally a 
late complication that is more common in lcSSc (20). Lung fibrosis 
can also develop separately from or in conjunction with pulmonary 
hypertension. Fibrosis can advance in a self- perpetuating manner 
and may not be driven solely by an immune- mediated process (21).
We believe SSc can be conceptualized as a family of similar dis-
eases—an idea supported by the identification of molecular subsets 
by whole- genome gene expression profiling, with distinct clinical and 
serologic features and recognized phases within some subtypes 
(22). The delayed emergence of new organ involvement and gradual 
progression of the disease provide clinicians with a realistic oppor-
tunity to impede disease progression and change disease course.
Why is disease- modifying therapy a challenge  
in SSc?
Many challenges exist in demonstrating disease- modifying 
effects in SSc patients. First, the disease is heterogeneous 
with different patterns of evolution among the clinical subsets, 
as previously outlined (5,23–25). Patients usually present with 
predominantly vasculopathic complications (such as RP, digital 
Figure  1. The usual timing of organ- specific manifestations 
in systemic sclerosis (SSc). ILD = interstitial lung disease; GIT = 
gastrointestinal tract; PBC = primary biliary cirrhosis. Adapted, 
with permission, from Steen V, Medsger TA. Systemic sclerosis. 
Lippincott Williams & Wilkins; 1996.
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ulcers, PAH, scleroderma renal crisis [SRC], and gastrointestinal 
involvement), predominately fibrotic complications (such as skin 
fibrosis, joint involvement, lung fibrosis, and cardiac fibrosis), or a 
combination of these features. Within each cutaneous subgroup, 
there is heterogeneity in internal organ involvement (18). Second, 
there are molecular differences in the skin gene expression data 
in patients with a similar phenotype. One such formulation identi-
fied 4 subsets based on skin gene expression data: normal- like, 
inflammatory, fibroproliferative, and limited (22,26). These sub-
sets help identify patients at risk for internal organ involvement, 
such as interstitial lung disease (ILD), as well as their response to 
current therapies (26,27). Measuring gene expression subsets in 
clinical trials, and possibly even in routine clinical care, may clearly 
distinguish and clarify patient heterogeneity in the near future 
and provide a window through which to understand and predict 
patient response to therapy. Third, the predictors of disease sta-
tus at a specific time point (incidence or severity of organ- based 
complications, which is largely influenced by autoantibodies) may 
differ from predictors of disease progression (28,29).
Unlike the Disease Activity Score in 28 joints (30), Clin-
ical Disease Activity Index (31), or other disease activity mea-
sures in RA, we lack reliable tools with which we can define 
the achievement of remission in SSc. In dcSSc, the modified 
Rodnan skin score (MRSS) (32), and recently, a combined 
responder index in dcSSc (American College of Rheumatology 
Combined Response Index in diffuse cutaneous Systemic Scle-
rosis [ACR CRISS] [33]—a composite end point that captures 
cardiopulmonary- renal involvement and change in MRSS, Health 
Assessment Questionnaire disability index [HAQ DI] [34], patient 
global assessment of disease activity, physician global assess-
ment of disease activity, and forced vital capacity percent pre-
dicted [FVC%]) are used as outcome measures to assess the 
efficacy of drugs. These measures have not been validated in 
lcSSc, and some of these may not perform well (35). Further, 
clinical heterogeneity of the disease does not allow for precise 
definition of global disease activity. Composite scores such as 
the revised European Scleroderma Research Group Activity 
Index (28) have been proposed but not widely accepted in the 
evaluation of disease activity. Novel approaches for assessing 
disease activity in SSc are currently under development (36).
Are there currently disease- modifying therapies 
for SSc?
Despite the limitations in disease activity measurement in 
SSc, treatment approaches directed toward specific biologic 
targets appear to be positively influencing outcomes in SSc 
(Supplementary Table 1, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41246/ 
abstract). This concept can be approached by categorizing 
SSc manifestations into vasculopathic, immunologic, or inflam-
matory involvement as well as tissue fibrosis.
Vasculopathy
The predominant vascular complications in SSc are RP, PAH, 
SRC, and digital ulcers. Morbidity and mortality are high in patients 
with PAH and SRC. RP and digital ulcers are chronic complica-
tions that can limit hand function, increase morbidity and disability 
(37), and impact HRQoL. Pathophysiologic mechanisms in SSc 
vasculopathy are characterized by initial vascular endothelial injury 
and dysfunction followed by vessel wall remodeling with intimal 
and medial thickening, leading to luminal narrowing, vascular stiff-
ness, and tissue hypoxia (38).
Pulmonary arterial hypertension. One of the relevant 
vasculopathic manifestations, which is associated with signifi-
cant mortality and morbidity in SSc patients, is PAH. The prev-
alence of PAH measured by right- sided heart catheterization in 
large cohorts of SSc patients ranges from 5% to 12% (39,40). 
SSc- PAH is associated with a worse outcome compared to 
idiopathic PAH because there are non–PAH- related factors in 
SSc like coexistent ILD- associated pulmonary hypertension, 
pulmonary venoocclusive disease, SSc- related myocardial dis-
ease, and later age at disease onset (41,42). Greater empha-
sis has been put on early screening and detection of SSc- PAH 
with the use of composite algorithms, allowing for the earlier 
institution of PAH- specific therapy (43–45). There is a grow-
ing body of evidence that this approach may improve mor-
bidity outcomes, although the effect on long- term mortality 
is unclear (46). The lower incidence of SSc- PAH in patients 
treated with dihydropyridine calcium antagonists offers a tan-
talizing glimpse into the potential disease- modifying actions 
of fairly modest vasodilator therapy on long- term outcomes 
in SSc (47).
There are multiple approved therapies for PAH manage-
ment that target 1 of the 3 pathogenic pathways: 1) endothelin 
antagonists, 2) nitric oxide (NO)/soluble guanylate cyclase (GC) 
agonists/stimulators, and 3) prostacyclin analogs (48). High- 
quality randomized controlled trials (RCTs) have shown that 
upfront or sequential combination therapies delay time to clinical 
worsening in PAH patients. Similar approaches with combina-
tion therapies have suggested efficacy in treating SSc- PAH. In 
a recent meta- analysis, combination therapy targeting PAH was 
demonstrated to have greater therapeutic efficacy than mono-
therapy in patients with SSc- PAH. There was a 27% reduction 
in clinical worsening (pooled relative risk 0.73 [95% confidence 
interval 0.60–0.89]) (P = 0.002) and probable improvement of 
exercise capacity in these patients (49). A recent trial of rituxi-
mab (RTX) in SSc- PAH showed trends of benefit on functional 
status (6- munute walk test) and pulmonary vascular resistance 
versus placebo (ClinicalTrials.gov identifier: NCT01086540), and 
there is also an ongoing trial of tocilizumab in the background 
of currently approved therapies (ClinicalTrials.gov identifier: 
NCT02676947) (50,51).
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Raynaud’s phenomenon and digital ulcers. In SSc, 
common and burdensome vascular manifestations include RP 
and digital ulcers. RP can be an early sign preceding the diag-
nosis of SSc, usually emerging prior to tissue fibrosis (52). RP is 
a manifestation of abnormal cutaneous vessel function involved 
in thermal regulation of blood flow (53). The presence of RP and 
the loss of normal regulation of cutaneous vascular tone are often 
predictors of SSc development—although they are not specific 
to SSc, cannot be used alone as predictors, and may be long- 
delayed symptoms (52,54).
Digital ulcers are a significant cause of morbidity, with ~50% 
of SSc patients developing digital ulcers during their disease 
course (18). Digital ulcers can be a sporadic phenomenon, 
but for some patients, they are recurrent, continuous, and/or 
refractory (55). Digital ulcers can lead to significant disability in 
the form of impaired hand function and increased pain, loss of 
employment, and medical complications like gangrene, cellulitis, 
osteomyelitis, and digital amputation. Progress has been made 
in secondary prevention, although with mixed results. Phos-
phodiesterase 5 (PDE5) inhibitors, especially sildenafil, can 
reduce the frequency of RP episodes in SSc (56). A recent RCT 
comparing the use of oral sildenafil (20 mg/3 times a day) to 
placebo favored sildenafil in significantly decreasing the num-
ber of digital ulcers at week 12, but did not meet the primary 
end point of time to healing (57). In SSc patients with refractory 
and recurrent digital ulcers, it has been shown that 62.5 mg of 
bosentan (an endothelin 1 receptor antagonist) 2 times a day 
over a 4- week- period, followed by 125 mg of bosentan 2 times a 
day can reduce the number of new digital ulcers in those with >4 
previous digital ulcers, without any effect on healing digital ulcers 
that already present (58,59). Intravenous (IV) prostanoid therapy 
improves digital ulcer healing and reduces the number of new 
digital ulcers. In 2 multicenter, double- blind, randomized trials, IV 
prostanoid therapy (iloprost 0.5–2.0 ng/kg/minute over 6 hours 
for 5 consecutive days) was associated with significant improve-
ment in the frequency of RP episodes and greater improvement 
in digital ulcer healing (60,61).
Scleroderma renal crisis. A major, life- threatening vascu-
lopathic manifestation of SSc is SRC (62). SRC is a rare compli-
cation that affects 2–15% of patients with SSc (11% of dcSSc 
patients and 4% of lcSSc patients) (40). SRC typically presents in 
patients with early, rapidly progressive dcSSc, often with the pres-
ence of anti- RNA polymerase III antibodies (63). The prognosis 
of SRC substantially improved in the 1980s with the introduction 
of angiotensin- converting enzyme (ACE) inhibitors for rapid blood 
pressure control and with additional antihypertensive agents as 
required (62). In a prospective analysis of 108 patients with SRC 
in a single center, patients who received ACE inhibitors (captopril 
[n = 47] and enalapril [n = 8]) had a significantly better survival rate 
at 1 year (76%) and 5 years (66%) compared to patients who did 
not receive ACE inhibitors (1 year [15%] and 5 years [10%]) (62). 
In another prospective trial, 145 patients with SRC treated with 
ACE inhibitors demonstrated survival rates of 90% and 85% at 
5 and 8 years, respectively, after onset of SRC (64). Furthermore, 
treatment with ACE inhibitors decreased the need for permanent 
dialysis (16). Overall, current patient survival is 70–82% at 1 year, 
but decreases to 50–60% at 5 years despite dialysis support.
In summary, there are therapies available for vascu-
lopathy that have disease- modifying effects, including 
improved HRQoL, morbidity, and survival. These effects 
are well- demonstrated for SRC and PAH with unequivocal 
benefits in clinical trials.
Immunoinflammatory involvement
The concept of ablating an autoreactive immune system 
followed by its replacement with a self- tolerant one (also called 
HSCT) has been successfully explored in SSc (7,8). Oral or pulse 
IV cyclophosphamide (CYC) therapy in individuals with symptom-
atic, established SSc- ILD has a significant, though modest, bene-
ficial effect on lung function, thickening of the skin, dyspnea, and 
HRQoL (65,66) and has no impact on long- term survival (67,68).
Three major prospective trials were initiated to examine the 
role of HSCT in SSc treatment—the Autologous Stem Cell Trans-
plantation International Scleroderma (ASTIS) trial (7), the American 
Scleroderma Stem Cell versus Immune Suppression trial (ASSIST) 
(8), and the Scleroderma: Cyclophosphamide Or Transplantation 
(SCOT) trial (6). These studies compared autologous HSCT (with 
and without radiation) to various IV CYC treatment regimens. All 
studies included patients with early dcSSc who had moderate- 
to- severe skin thickness and internal organ involvement (lung 
involvement largely accounted for the vast majority of patients). 
Study patients were those who were predicted to have disease 
activity that would rapidly progress. Although there were substan-
tial differences in the study design among these trials, the results 
of the 3 studies allowed for valid conclusions to be drawn with 
regard to the effect of HSCT in patients with early SSc who have 
progressive skin and/or lung involvement. The notable observa-
tions of outcomes among patients who underwent HSCT were 
as follows: 1) clinically meaningful improvement in skin thickness, 
2) overall stabilization of lung function, 3) clinically meaningful 
improvement in HRQoL, 4) overall survival benefit (although higher 
short- term serious adverse events in the ASTIS and SCOT trials 
and a higher mortality rate during the first year after transplan-
tation in patients who underwent HSCT in the ASTIS trial were 
recorded), and 5) the observation that SSc heart disease (myo-
cardial involvement and PAH) appears to be the main driver of 
transplantation- related death (6–8,69).
In summary, HSCT trials provide clear evidence of immune- 
mediated pathogenesis in SSc and document long- term, clinically 
important disease modification in early aggressive disease.
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Tissue fibrosis
Three important manifestations of tissue fibrosis include skin 
fibrosis, ILD, and myocardial fibrosis.
Skin involvement. Skin fibrosis is a cardinal manifestation 
and is observed in most SSc patients, although a small minority 
have no skin involvement (SSc without scleroderma) (17,70). Skin 
fibrosis is associated with significant morbidity due to pruritis, 
digital ulcers, skin tightness, and skin ulcers at other sites as well 
as markedly decreased function. A rapidly progressive pheno-
type of skin fibrosis is associated with a higher mortality rate due 
to progressive internal organ involvement (71). Recently, immu-
nosuppressive therapies such as CYC, mycophenolate mofetil 
(MMF), and biologic response modifiers (such as abatacept 
and tocilizumab) have been evaluated for their effects on skin 
thickening in dcSSc. Based on the data from Scleroderma Lung 
Studies I and II (SLS I and II), treatment of patients with dcSSc 
with CYC or MMF resulted in clinically meaningful improvement 
in the MRSS as compared to those receiving placebo (72). In 
a recent RCT, abatacept treatment (versus placebo) resulted in 
clinically meaningful change in ACR CRISS scores despite no 
significant change in MRSS. Decline in MRSS over 12 months 
was clinically and significantly higher in the abatacept group 
versus the placebo group for the inflammatory and normal- like 
skin gene expression subsets (73). In another RCT, subcutane-
ous tocilizumab trended to improve MRSS but also highlighted 
a marked heterogeneity in individual response (74).
Interstitial lung disease in SSc. ILD is present in 70–80% 
of patients with SSc, with ~20–25% developing symptomatic ILD 
(75,76). ILD is the leading cause of death in SSc and accounts 
for over one- third of SSc- related deaths (25). Immunosuppres-
sive therapies have been consistently explored for the treatment 
of SSc- ILD, with differing results.
In SLS I, patients with SSc- ILD received oral CYC or match-
ing placebo for 12 months and were followed up in a double- blind 
trial for an additional 12 months (65). After 12 months, significant 
(though modest) treatment effects of CYC versus placebo were 
observed on FVC and total lung capacity (TLC), but not on dif-
fusing capacity for carbon monoxide (DLco). The effect on FVC 
persisted at 18 months in the CYC group (although CYC was 
no longer being given), but was no longer present at 24 months. 
Additionally, CYC improved dyspnea, HRQoL, and functional abil-
ity. CYC treatment did not change long- term survival, a finding 
that was not unexpected, given that the treatment was admin-
istered for only 1 year (68). In SLS II, patients with SSc- ILD were 
randomized to receive either 3 grams of oral MMF each day for 
24 months or oral CYC each day for 12 months (followed by pla-
cebo for 12 months) (77). No significant differences were observed 
in the long- term survival or organ failure for patients who randomly 
received CYC versus MMF.
In a recent long- term follow- up of patients in SLS I and II, 
the majority of patients died of complications related to SSc, 
with respiratory failure from end- stage lung disease as one of the 
leading causes of death (68). Data from a phase III clinical trial 
suggested that interleukin- 6 inhibition in early SSc with elevated 
C- reactive protein levels led to stabilization of FVC% in the tocili-
zumab group versus a clinically meaningful decline in the placebo 
group over 48 weeks (treatment difference of 4.2%; P = 0.0002) 
(74). The mean ± SD FVC% was 82.1 ± 14.8 at baseline, which 
highlights the benefit of treating patients with subclinical ILD who 
have high- risk features (early dcSSc and elevated C- reactive 
protein levels). RTX therapy in SSc has shown promising effects 
on both ILD and skin thickening. In a recent open- label, ran- 
domized, controlled trial of RTX treatment (administered in 2 doses 
of 1,000 mg each) versus monthly pulse CYC therapy, a pop-
ulation of 60 treatment- naive, anti–Scl- 70 positive patients with 
early dcSSc and ILD were analyzed (78). FVC% was improved in 
the RTX group at the end of 6 months (+5.8% in the RTX group 
versus −1.2% in the CYC group). The data, overall, suggest that 
targeted biologic therapies may have disease- modifying effect in 
ILD with regard to preservation of lung function (74,79).
A recent 52- week, placebo- controlled RCT, treatment with 
nintedanib, a tyrosine kinase inhibitor, slowed the progression of 
FVC decline in SSc- ILD, which led to approval by the Food and 
Drug Administration (80). The adjusted annual rate of decline in 
FVC was lower in the nintedanib- treated group than in the placebo- 
treated group (difference 41.0 ml per year; P = 0.04), although no 
clinical benefits for other manifestations of SSc, dyspnea, or func-
tion were observed. Overall, ~50% of the patients were receiving 
MMF at baseline. Among these patients who had received prior 
MMF treatment, those who were given placebo experienced a 
smaller decline in the FVC, and in the nintedanib group, the mag-
nitude of the nintedanib treatment effect on the FVC was lower. 
The rate of gastrointestinal adverse events was higher in the 
nintedanib group versus the placebo group. Currently, there is an 
ongoing double- blind RCT (SLS III) comparing the combination of 
MMF with pirfenidone (an antifibrotic agent approved for treating 
idiopathic pulmonary fibrosis) versus MMF alone in the treatment 
of SSc- ILD (ClinicalTrials.gov identifier: NCT03221257) (80).
Cardiac involvement. Cardiac involvement is marked by 
myocardial fibrosis and has been reported in >50% of autopsies 
(81). It is frequently encountered in SSc patients, is often asymp-
tomatic, and is associated with higher mortality rate (23,40,63). 
Alteration in heart rhythm with hemodynamically significant 
arrhythmias, including ventricular tachycardia, is associated with 
high mortality. Apart from medical therapy for systolic heart fail-
ure, other supportive measures such as implantable cardioverter 
 defibrillators, dual- chamber pacing, or cardiac transplantation may 
be necessary.
In summary, with regard to fibrosis, data suggest that 
improvement in skin involvement may not be an achievable end 
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point in trials at present due to measurement tools that lack sensi-
tivity, difficulty in defining sufficiently uniform entry criteria for trials, 
and individual heterogeneity in clinical manifestations. However, 
fibrosis in other organs, particularly in the lungs, may be amenable 
to treatment with biologic agents, and recently, a tyrosine kinase 
inhibitor.
Other unmet needs
There are other disabling manifestations in SSc wherein the 
pathogenesis is poorly understood and/or does not have vali-
dated outcome measures. The gastrointestinal tract is involved 
in up to 95% of patients with SSc and is a presenting feature in 
~10% of patients (82). Gastrointestinal involvement causes sub-
stantial morbidity and is responsible for 6–12% of deaths in SSc 
patients. Calcinosis, characterized by the deposition of insoluble 
calcium salts in the skin and subcutaneous tissue, is observed 
in ~25% of patients with SSc (83). In SSc, arthritis and joint 
contractures of the small and large joints are commonly seen in 
about one- third of patients, with the presence of large joint con-
tractures being predictive of mortality (84,85). Telangiectasias, 
while themselves harmless in the skin, can be a major source 
of body image dissatisfaction in addition to a predecessor of 
pulmonary vascular disease, which would make them valu- 
able markers of disease progression. They may also be a source 
of gastrointestinal bleeding, leading to potential increased mor-
bidity (86). These manifestations are often unaccounted for 
as a disease outcome in pharmacologic trials and need to be 
included in future trials with consistent ways to measure the 
treatment  outcome.
What should modification of disease course look 
like today, and how should it be measured?
Ideal disease- modifying therapy should halt the progression 
of the disease and hopefully induce remission, and preferably also 
reverse some major organ complications, as seen in the recent 
HSCT trials on fibrotic complications (Figure 2). It is reasonable 
to expect disease- modifying therapy to stabilize organ function 
without any further worsening of other domains.
Reliable, valid, and responsive outcome measures are needed 
to assess the effect of disease- modifying therapy. Based on the 
RCTs conducted for key clinical manifestations in SSc (shown in 
Supplementary Table 1, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41246/ 
abstract), lessons have been learned about outcome measures. 
MRSS (a measure of skin thickness) has shown natural regression, 
despite enrichment for early disease and/or elevated acute reac-
tants at baseline (73,74,87). Combined measures of response, 
analogous to such measures used in RA, may be a way forward.
In the RCTs of abatacept and tocilizumab in dcSSc, MRSS 
was not able to distinguish the efficacy of active therapies com-
pared to placebo, but there were statistically significant and 
clinically meaningful improvements in the ACR CRISS, a com-
bined measure designed to capture the global or holistic evalu-
ation in early SSc. In the tocilizumab trial, the ACR CRISS was 
driven by improvement in and stabilization of FVC%, whereas 
results from the HAQ DI and physician global assessments of 
disease activity were statistically significant in the abatacept trial. 
ACR CRISS core set of outcome measures should be included in 
forthcoming clinical trials.
Figure 2. The long-term impact of ideal disease-modifying therapy (DMT), in comparison to hematopoietic stem cell therapy (HSCT), on 
outcomes in systemic sclerosis (SSc) with a predominantly fribotic phenotype. DLco = diffusing capacity for carbon monoxide; FVC = forced 
vital capacity; MRSS = modified Rodnan skin score; HAQ = Health Assessment Questionnaire.
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Another example is the global rank composite score used in 
the SCOT trial, which utilized a hierarchical combined measure 
of response. In SSc- ILD, a combination of objective measures 
(FVC, DLco, and lung imaging scores of fibrosis) and a patient- 
reported measure of dyspnea demonstrated responses and, in 
combination, could be utilized to increase sensitivity and dis-
crimination. At this point, FVC currently appears to be a valid 
end point that could be used in these types of clinical trials if 
given regulatory approval (65,66). In PAH, recent successes 
have been achieved with clinically meaningful end points such 
as time to clinical worsening, which is a combined end point 
influenced by morbidity (such as worsening performance on 
6- minute walk distance, worsening of New York Heart Asso-
ciation functional classification, requirement of additional PAH 
therapy, and hospitalizations due to PAH) or all- cause mortality 
as a valid end point in PAH (88).
How should we define remission and low disease 
activity in SSc?
Based on our current understanding and constraints with 
testing, disease remission, which we define as the absence of 
disease activity, may not be achievable in the setting of SSc due 
to the heterogeneity of the disease and the few positive trials that 
have been conducted to this effect. Buoyed by the outcomes in 
PAH and HSCT trials, it is time to start creating a framework for 
the conceptual definition for low disease activity in SSc.
First, low disease activity in SSc should be an individual dis-
ease state (on or off therapy). Second, low disease activity (when 
sustained over a period of time) should be associated with bet-
ter outcomes and positive effects on HRQoL (89). Future studies 
should define the time period of low disease activity that demon-
strates a favorable impact on outcomes and HRQoL, although this 
will differ based on organ involvement. Third, the distinction between 
what represents disease activity and what represents damage is a 
challenge that is currently an area of investigation (36). Activity is 
defined as the component of disease severity that is largely revers-
ible and may result in little or no damage in the future. Damage is 
the component of severity that is largely irreversible. In Figure 3, we 
lay out a preliminary proposal to define low disease activity for the 
different manifestations in SSc (65,66,80,90–93). This is an author- 
driven preliminary proposal, influenced by data obtained from RCTs 
and observational studies. This proposal will need rigorous testing 
and validation using a consensus methodology in future studies.
Figure 3. Suggested parameters for low disease activity state (LDA) in systemic sclerosis (SSc). These are author- driven preliminary proposals, 
influenced by data from randomized control trials and observational studies, which will need further testing and validation in future investigations. 
dcSSc = diffuse cutaneous SSc; MRSS = modified Rodnan skin score; HAQ DI = Health Assessment Questionnaire disability index; PGA = 
patient global assessment of disease activity; ILD = interstitial lung disease; FVC = forced vital capacity (percent predicted); RCS = Raynaud’s 
Condition Score; RP = Raynaud’s phenomenon; DU = digital ulcer; VAS = visual analog scale; SHAQ = Scleroderma Health Assessment 
Questionnaire; SRC = scleroderma renal crisis; PAH = pulmonary arterial hypertension; PAP = pulmonary arterial pressure; ESC/ERS = European 
Society of Cardiology and European Respiratory Society; NYHA = New York Heart Association; 6MWD = 6- minute walking distance; RAP = 
right atrial pressure; CI = cardiac index; BNP = B-type natriuretic peptide; NT-ProBNP = N-terminal proBNP; REVEAL = Registry to Evaluate 
Early and Long- Term PAH Disease Management; RHC = right heart catheterization.
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Conclusions
Using data and outcome measures from recent clinical trials 
in SSc, we propose a conceptual framework on how to define 
low disease activity for different organ- specific manifestations in 
SSc. Disease- modifying therapies (such as HSCT in dcSSc, for 
example) and their effect on SSc should be considered in future 
investigations.
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